Literature DB >> 19444595

Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide.

Clement G Yedjou1, Paul B Tchounwou.   

Abstract

Arsenic trioxide (As(2)O(3)) has recently been successfully used to treat all trans retinoic acid (ATRA) resistant relapsing acute promyelocytic leukemia. However, its molecular mechanisms of action are poorly understood. In the present study, we used the human leukemia (HL-60) cell line as a test model to study the cellular and molecular mechanisms of anti-cancer properties of As(2)O(3). We hypothesized that As(2)O(3)-induced expression of stress genes and related proteins may play a role in the cellular and molecular events leading to cell cycle modulation in leukemic cells. To test this hypothesis, we performed Western blot analysis to assess the expression of specific cellular response proteins including p53, c-fos, RARE, Cyclin A, and Cyclin D1. Densitometric analysis was performed to determine the relative abundance of these proteins. Western Blot and densitometric analyses demonstrated a strong dose-response relationship with regard to p53 and RARE expression within the dose-range of 0-8 microg/ml. Expression of c-fos was slightly up-regulated at 2 microg/ml, and down-regulated within the dose-range of 4-8 microg/ml. A statistically significant down-regulation of this protein was detected at the 6 and 8 microg/ml dose levels. No statistically significant differences (p > 0.05) in Cyclin D1 expression was found between As(2)O(3)-treated cells and the control. Cyclin A expression in As(2)O(3)-treated HL-60 cells was up-regulated at 6 microg/ml, suggesting that it is required for S phase and passage through G(2) phase in cell cycle progression. Taken together, these results indicate that As(2)O(3) has the potential to induce cell cycle arrest through activation of the 53-kDa tumor suppressor protein and repression of the c-fos transcription factor. Up-regulation of RARE by As(2)O(3) indicates that its cytotoxicity may be mediated through interaction/binding with the retinoic acid receptor, and subsequent inhibition of growth and differentiation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19444595      PMCID: PMC2855208          DOI: 10.1007/s11010-009-0160-z

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  48 in total

1.  Molecular characterization of the cyclin-dependent kinase inhibitor p27 promoter.

Authors:  Y Zhang; S C Lin
Journal:  Biochim Biophys Acta       Date:  1997-09-12

2.  Arsenite inhibits Ras-dependent activation of ERK but activates ERK in the presence of oncogenic Ras in baboon vascular smooth muscle cells.

Authors:  G Daum; J Pham; J Deou
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

3.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.

Authors:  W K Hong; S M Lippman; L M Itri; D D Karp; J S Lee; R M Byers; S P Schantz; A M Kramer; R Lotan; L J Peters
Journal:  N Engl J Med       Date:  1990-09-20       Impact factor: 91.245

4.  In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.

Authors:  G Q Chen; J Zhu; X G Shi; J H Ni; H J Zhong; G Y Si; X L Jin; W Tang; X S Li; S M Xong; Z X Shen; G L Sun; J Ma; P Zhang; T D Zhang; C Gazin; T Naoe; S J Chen; Z Y Wang; Z Chen
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

Review 5.  The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects.

Authors:  Ann M Bode; Zigang Dong
Journal:  Crit Rev Oncol Hematol       Date:  2002-04       Impact factor: 6.312

6.  pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells.

Authors:  R J Lee; C Albanese; R J Stenger; G Watanabe; G Inghirami; G K Haines; M Webster; W J Muller; J S Brugge; R J Davis; R G Pestell
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

7.  Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice.

Authors:  T C Wang; R D Cardiff; L Zukerberg; E Lees; A Arnold; E V Schmidt
Journal:  Nature       Date:  1994-06-23       Impact factor: 49.962

8.  Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid.

Authors:  T R Breitman; S J Collins; B R Keene
Journal:  Blood       Date:  1981-06       Impact factor: 22.113

9.  Cyclin A is required for the onset of DNA replication in mammalian fibroblasts.

Authors:  F Girard; U Strausfeld; A Fernandez; N J Lamb
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

10.  Cyclin A is required at two points in the human cell cycle.

Authors:  M Pagano; R Pepperkok; F Verde; W Ansorge; G Draetta
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

View more
  13 in total

1.  Toxicity of depleted uranium complexes is independent of p53 activity.

Authors:  Ellie Heintze; Camille Aguilera; Malia Davis; Avery Fricker; Qiang Li; Jesse Martinez; Matthew J Gage
Journal:  J Inorg Biochem       Date:  2010-10-29       Impact factor: 4.155

2.  Arsenite causes down-regulation of Akt and c-Fos, cell cycle dysfunction and apoptosis in glutathione-deficient cells.

Authors:  Geetha M Habib
Journal:  J Cell Biochem       Date:  2010-05-15       Impact factor: 4.429

3.  Therapeutic Potential of Arsenic Trioxide (ATO) in Treatment of Hepatocellular Carcinoma: Role of Oxidative Stress in ATO-Induced Apoptosis.

Authors:  Erika B Dugo; Clement G Yedjou; Jacqueline J Stevens; Paul B Tchounwou
Journal:  Ann Clin Pathol       Date:  2017-01-04

4.  Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells.

Authors:  Clement Yedjou; Paul Tchounwou; John Jenkins; Robert McMurray
Journal:  J Hematol Oncol       Date:  2010-08-26       Impact factor: 17.388

Review 5.  Heavy metal toxicity and the environment.

Authors:  Paul B Tchounwou; Clement G Yedjou; Anita K Patlolla; Dwayne J Sutton
Journal:  Exp Suppl       Date:  2012

6.  Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663.

Authors:  Pan Jian; Zhao Wen Li; Tao Yan Fang; Wang Jian; Zhou Zhuan; Liao Xin Mei; Wu Shui Yan; Ni Jian
Journal:  J Hematol Oncol       Date:  2011-04-25       Impact factor: 17.388

7.  Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells.

Authors:  Sanjay Kumar; Paul B Tchounwou
Journal:  Oncotarget       Date:  2015-12-01

8.  Inhibition of early T cell cytokine production by arsenic trioxide occurs independently of Nrf2.

Authors:  Kelly R VanDenBerg; Robert A Freeborn; Sheng Liu; Rebekah C Kennedy; Joseph W Zagorski; Cheryl E Rockwell
Journal:  PLoS One       Date:  2017-10-19       Impact factor: 3.240

9.  Multifactorial Modes of Action of Arsenic Trioxide in Cancer Cells as Analyzed by Classical and Network Pharmacology.

Authors:  Mona Dawood; Sami Hamdoun; Thomas Efferth
Journal:  Front Pharmacol       Date:  2018-02-27       Impact factor: 5.810

10.  Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia.

Authors:  Clement Yedjou; Laurette Thuisseu; Christine Tchounwou; Maria Gomes; Carolyn Howard; Paul Tchounwou
Journal:  Arch Drug Inf       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.